HiFiBiO Therapeutics
- Founded: 2013
- Location: Paris, France
- Employee range: 50 - 200
- Clinical stage: Clin1
- Therapy area: Solid tumors
- Drug types: ONC, IMM
- Lead product: HFB200301
- Product link: https://hifibio.com/pipeline/
- Funding: $75M D Jun 2021; $67M C Aug 2019; $37.5M B May 2018
hifibio.com linkedin.com job board
Short description:
Single cell technologies for drug discovery
Drug notes:
HFB301001 Clin1 solid tumors; HFB200603 Clin1 solid tumors; HFB200902 Clin0 myeloid malignancies, solid tumors; HFB101110 Clin0 solid tumors; HFB100204 Clin0 autoimmune disease, oncology
Long description:
HiFiBio Therapeutics is using the human immune system to treat cancer and autoimmune diseases. The immune system plays an important role in detecting and clearing diseased cells, but it can become defective in many patients. HiFiBio is unlocking the power of the immune system with antibody immunotherapies, optimized for patient efficacy. To discover biomarkers to effectively match their best therapeutic to each patient, HiFiBio is using their Drug Intelligent Science (DIS) technology. DIS uses single-cell analytics with AI-based data analysis from patient samples to overcome patient heterogeneity, scaling requirements to transform drug discovery. HiFiBio is currently enrolling cancer patients from DIS selected indications into two clinical studies.
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com